Savoy Pharmaceuticals Your Life is Our Business family

TK1 Publications


  1. Prognostic significance of thymidine kinase activity in bladder carcinoma. Mizutani Y, Wada H, Yoshida O, Fukushima M, Kamoi K, Miki T. Cancer. 2002 Nov 15;95(10):2120-5
  2. Modulation of the feedback regulation of thymidine kinase activity by pH in 647V cells (human bladder cancer cell line). MA Vazquez-Padua, K Kunugi, C Risueno and PH Fischer. Cancer Research, Vol 49, Issue 20 5644-5649, Copyright© 1989 by American Association for Cancer Research



  1. Correlations of dihydropyrimidine dehydrogenase, thymidine phosphorylase and thymidine kinase activities in strongly and weakly malignant cultured murine neuroblastoma cells. Williams CS, Tuchman M. Int J Cancer 1989 May 15;43(5):901-4.



  1. A comparative study: immunohistochemical detection of cytosolic thymidine kinase and proliferating cell nuclear antigen in breast cancer. Mao Y, Wu J, Wang N, He L, Wu C, He Q, Skog S. Cancer Invest 2002;20(7-8):922-31.
  2. Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy. Foekens JA, Romain S, Look MP, Martin PM, Klijn JG. Cancer Res 2001 Feb 15;61(4):1421-5.
  3. Thymidine kinase 1 immunoassay: a potential marker for breast cancer. Zhang F, Li H, Pendleton AR, Robison JG, Monson KO, Murray BK, O'Neill KL. Cancer Detect Prev 2001;25(1):8-15.
  4. DNA-synthesizing enzymes in breast cancer (thymidine kinase, thymidylate synthase and thymidylate kinase): association with flow cytometric S-phase fraction and relative prognostic importance in node-negative premenopausal patients. Romain S, Bendahl PO, Guirou O, Malmstrom P, Martin PM, Ferno M. Int J Cancer. 2001 Jan 20;95(1):56-61.
  5. Prognostic of DNA-synthesizing enzyme activities (thymidine kinase and thymidylate synthase) in 908 T1-T2, N0-N1, M0 breast cancers: a retrospective multicenter study. Romain S, Spyratos F, Descotes F, Daver A, Rostaing-Puissant B, Bougnoux P, Colonna M, Bolla M, Martin PM. Int J Cancer. 2000 Sep 15;87(6):860-8.
  6. The clinical significance of thymidine kinase 1 measurement in serum of breast cancer patients using anti-TK1 antibody. He Q, Zou L, Zhang PA, Lui JX, Skog S, Fornander T. Int J Biol Markers 2000 Apr-Jun;15(2):139-46.
  7. EORTC receptor and biomarker study group report analytical and technical evaluation of a thymidine kinase radio-enzymatic assay in breast cancer cytosols. Span P, Heuvel J, Romain S, Piffanelli A, Martin PM, Geurts-Moespot A, Sweep F. Anticancer Res 2000 Mar-Apr;20(2A):681-7.
  8. Technical evaluation of thymidine kinase assay in cytosols from breast cancers. EORTC Receptor Study Group Report. Romain S, Spyratos F, Guirou O, Deytieux S, Chinot O, Martin PM. Eur J Cancer 1994;30A(14):2163-5.
  9. Relative activities of thymidylate synthetase and thymidine kinase in human mammary tumours. Sakamoto S, Ebuchi M, Iwama T. Anticancer Res 1993 Jan-Feb;13(1):205-7.
  10. Can thymidine kinase levels in breast tumors predict disease recurrence? O'Neill KL, Hoper M, Odling-Smee GW. J Natl Cancer Inst 1992 Dec 2;84(23):1825-8.
  11. Thymidine kinase activities in mononuclear leukocytes and serum from breast cancer patients. McKenna PG, O'Neill KL, Abram WP, Hannigan BM. Br J Cancer 1988 Jun;57(6):619-22.
  12. Thymidine kinase: the future in breast cancer prognosis. V. Puri and M. Bhatia. P.D. hinduja National Hospital and Medical Reserch Centre, Mahim, Mumbai 400016, India.



  1. Clinical value of thymidine kinase in patients with cervical carcinoma. Fujiwaki R, Hata K, Moriyama M, Iwanari O, Katabuchi H, Okamura H, Miyazaki K. Department of Obstetrics and Gynecology, Shimane Medical University, Izumo, Japan. Oncology. 2001;61(1):47-54.
  2. Modulation of the cytotoxicity of 3'-azido-3'-deoxythymidine and methotrexate after transduction of folate receptor cDNA into human cervical carcinoma: identification of a correlation between folate receptor expression and thymidine kinase activity. Sun XL, Jayaram HN, Gharehbaghi K, Li QJ, Xiao X, Antony AC. Cancer Res 1999 Feb 15;59(4):940-6.



  1. Effects of carcinogenesis on colonic thymidine kinase activity in familial adenomatous polyposis. Sakamoto S, Kasahara N, Kudo H, Iwama T. Medical Research Institute, Tokyo Medical and Dental University, Japan. Carcinogenesis 1992 May;13(5):873-6.
  2. Activity of thymidylate synthetase, thymidine kinase and galactokinase in primary and xenografted human colorectal cancers in relation to their chromosomal patterns. Bardot V, Luccioni C, Lefrancois D, Muleris M, Dutrillaux B. CEA/DSV/DPTE/LCG, Fontenay aux roses, France. Int J Cancer 1991 Mar 12;47(5):670-4.
  3. Overexpression of DNA replication and repair enzymes in cisplatin-resistant human colon carcinoma HCT8 cells and circumvention by azidothymidine. Scanlon KJ, Kashani-Sabet M, Sowers LC. Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA 91010. Cancer Commun 1989;1(4):269-75.
  4. Alterations in colonic thymidine kinase enzyme activity induced by consumption of various dietary fibers. Calvert RJ, Reicks M. Experimental Nutrition Branch, U.S. Food and Drug Administration, Washington D.C. 20204. Proc Soc Exp Biol Med 1988 Oct;189(1):45-51.
  5. Biochemical tissue markers of human colorectal carcinoma. Aviram R, Deutsch A, Patya M, Nordenberg J, Mor C, Reiss R, Novogrodsky A. Department of Surgery B, Rogoff Medical Research Institute, Petah Tiqva, Israel. Dis Colon Rectum 1988 Mar;31(3):176-80.
  6. Increased activities of thymidine kinase isozymes in human colon polyp and carcinoma. Sakamoto S, Sagara T, Iwama T, Kawasaki T, Okamoto R. Carcinogenesis 1985 Jun;6(6):917-9.
  7. Human colon tumors enzymic and histological characteristics. Herzfeld A, Legg MA, Greengard O. Cancer 1978 Sep;42(3):1280-3.



  1. Thymidine kinase and thymidylate synthetase activities in human gastric cancer. Kawachi Y. Second Department of Surgery, Tokyo Medical and Dental University, Japan. Nippon Geka Gakkai Zasshi 1993 Sep;94(9):993-9.



  1. Significance of thymidine kinase activity in renal cell carcinoma. Mizutani Y, Wada H, Yoshida O, Fukushima M, Nakao M, Miki T. Department of Urology, Kyoto Prefectural University of Medicine, Japan. J Urol 2003 Feb;169(2):706-9.
  2. Mice deficient for cytosolic thymidine kinase gene develop fatal kidney disease. Dobrovolsky VN, Bucci T, Heflich RH, Desjardins J, Richardson FC. Mol Genet Metab 2003 Jan;78(1):1-10.
  3. Expression of genes involved in chemoresistance, proliferation and apoptosis in clinical samples of renal cell carcinoma and correlation with clinical outcome. Oudard S, Levalois C, Andrieu JM, Bougaran J, Validire P, Thiounn N, Poupon MF, Fourme E, Chevillard S. Anticancer Res 2002 Jan-Feb;22(1A):121-8.



  1. Expression of genes for certain enzymes of pyrimidine and purine salvage pathway in peripheral blood leukocytes collected from patients with Graves’ or Hashimoto’s disease. Karbownik M, Brzezianska E, Zasada K, Lewinski A. J Cell Biochem 2003 Jun 1;89(3):550-5.
  2. Predictive value of serum thymidine kinase level for Ig-V mutational status in B-CLL. C Magnac, R Porcher, F Davi, J Nataf, B Payelle-Brogard, RP Tang, P Oppezzo, V Levy, G Dighiero and F Ajchenbaum-Cymbalista. Leukemia (2003) 17, 133-137.
  3. Deoxynucleoside anabolic enzyme levels in acute myelocytic leukemia and chronic lymphocytic leukemia cells. Jacobsson B, Albertioni F, Eriksson S. Cancer Lett 2001 Apr 26;165(2):195-200.
  4. Activity of thymidine kinase and of polymerase alpha as well as activity and gene expression of deoxycytidine deaminase in leukemic blasts are correlated with clinical response in the setting of granulocyte-macrophage colony-stimulating factor-based priming before and during TAD-9 induction therapy in acute myeloid leukemia. Jahns-Streubel G, Reuter C, Auf der Landwehr U, Unterhalt M, Schleyer E, Wormann B, Buchner T, Hiddemann W. Blood 1997 Sep 1;90(5):1968-76.
  5. Overexpression of human thymidine kinase mRNA without corresponding enzymatic activity in patients with chronic lymphatic leukemia. Kristensen T, Jensen HK, Munch-Petersen B. Leuk Res 1994 Nov;18(11):861-6.
  6. Fetal thymidine kinase (TK1) in hairy cell leukaemia. Ellims PH, Gan TE, van der Weyden MB. Scand J Haematol 1983 Feb;30(2):141-4.



  1. Activity of the cytosolic isozyme of thymidine kinase in human primary lung tumors with reference to malignancy. Yusa T, Yamaguchi Y, Ohwada H, Hayashi Y, Kuroiwa N, Morita T, Asanagi M, Moriyama Y, Fujimura S. Cancer Res 1988 Sep 1;48(17):5001-6.
  2. Enzyme activities in human fetal and neoplastic tissues. Herzfeld A, Greengard O. Cancer 1980 Nov 1;46(9):2047-54.



  1. Serum thymidine kinase and soluble interleukin-2 receptor predict recurrence of malignant lymphoma. Wakao D, Murohashi I, Tominaga K, Yoshida K, Kishimoto K, Yagasaki F, Itoh Y, Itoh K, Sakata T, Kawai N, Kayano H, Suzuki T, Matsuda A, Hirashima K, Bessho M. Ann Hematol 2002 Mar;81(3):140-6. Epub 2002 Feb 09.
  2. Thymidine kinase and thymidine phosphorylase activities in various types of leukaemia and lymphoma. Vertongen F, Fondu P, van den Heule B, Cauchie C, Mandelbaum IM. Tumour Biol 1984;5(6):303-11.



  1. Pyrimidine and purine activities in non-Hodgkin’s lymphoma. Correlation with histological status and survival. Gan TE, Finch PD, Brumley JL, Hallam LJ, van der Weyden MB. Eur J Cancer Clin Oncol 1984 Mar;20(3):361-8.
  2. Prognostic relevance of thymidine kinase isozymes in adult non-Hodgkin’s lymphoma. Ellims PH, Eng Gan T, Medley G, Van Der Weyden MB. Blood 1981 Nov;58(5):926-30.



  1. Thymidine kinase in epithelial ovarian cancer: relationship with the other pyrimidine pathway enzymes. Fujiwaki R, Hata K, Nakayama K, Moriyama M, Iwanari O, Katabuchi H, Okamura H, Sakai E, Miyazaki K. Int J Cancer. 2002 May 20;99(3):328-35.
  2. Histologic and immunohistochemical analysis of tissue response to adenovirus-mediated herpes simplex thymidine kinase gene therapy of ovarian cancer. Hasenburg A, Fischer DC, Tong XW, Rojas-Martinez A, Nyberg-Hoffman C, Orlowska-Volk M, Kohlberger P, Kaufman RH, Ramzy I, Aguilar-Cordova E, Kieback DG. Int J Gynecol Cancer 2002 Jan-Feb;12(1):66-73.
  3. Differences in thermostability of thymidine kinase isoenzymes in normal ovary and ovarian carcinoma. Demeter A, Abonyi M, Look KY, Keszler G, Staub M, Weber G. Anticancer Res. 2001 Jan-Feb;21(1A):353-8.
  4. Serum thymidine kinase levels are elevated and exhibit diurnal variations in patients with advanced ovarian cancer. Hallek M, Touitou Y, Levi F, Mechkouri M, Bogdan A, Bailleul F, Senekowitsch R, Emmerich B. Clin Chim Acta 1997 Nov 28;267(2):155-66.
  5. Increased thymidine kinase and thymidylate synthase activities in human epithelial ovarian carcinoma. Look KY, Moore DH, Sutton GP, Prajda N, Abonyi M, Weber G. Anticancer Res 1997 Jul-Aug;17(4A):2353-6.



  1. EVALUATION OF PROLIFERATING CELLS FROM PROSTATE CARCINOMA BY AN ANTIBODY AGAINST THYMIDINE KINASE. No 126 (P). Wang Naining, He Qimin , Skog Sven , Eriksson Staffan and Tribukait Bernhard. Department of Oncology and Pathology, Karolinska Institute, Stockholm, Sweden.